QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 3, 2015-05 ,pp. : 436-443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does previous chemotherapy‐induced nausea and vomiting predict postoperative nausea and vomiting?

By  

ACTA ANAESTHESIOLOGICA SCANDINAVICA, Vol. 59, Iss. 9, 2015-10 ,pp. : 1145-1153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors and Secondary Prophylaxis with Aprepitant

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 30-34

Karger

Access to resources Recommend Favorite

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT₃ receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

By Schwartzberg Lee   Morrow Gary   Balu Sanjeev   Craver Chris   Gayle Julie   Cox David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1613-1622

Informa Healthcare

Access to resources Recommend Favorite

The NK1 receptor antagonist aprepitant attenuates NK1 agonist‐induced scratching behaviour in the gerbil after intra‐dermal, topical or oral administration

By  

EXPERIMENTAL DERMATOLOGY (ELECTRONIC), Vol. 24, Iss. 4, 2015-04 ,pp. : 312-314

John Wiley & Sons Inc

Access to resources Recommend Favorite